Physician profile
Gregory Moran
NPI 1871606780
$4,556.87
in general payments reported to CMS, 2019-2025
41 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $272 · 2021: $204 · 2022: $634 · 2023: $1,248 · 2024: $820 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.25 | 2019-2025 | |
| Gilead Sciences, INC. | $511.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $385.88 | 2019-2023 | Farxiga |
| Abbott Laboratories | $324.83 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Confirm Rx |
| Glaxosmithkline, LLC. | $280.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $243.05 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $152.68 | 2019-2023 | |
| Lilly USA, LLC | $131.32 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $113.83 | 2023-2025 | Veozah, Myrbetriq |
| Genentech USA, INC. | $108.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $101.37 | 2019-2023 | Belsomra, Steglatro |
| Antares Pharma, INC. | $95.42 | 2020-2023 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $93.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $89.47 | 2024-2025 | Apretude |
| Idorsia Pharmaceuticals US INC | $80.57 | 2022-2023 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.